Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

26.88 -0.09 (-0.35%)

Streaming Delayed Price Updated: 2:12 PM EST, Feb 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	546,621
Open	26.92
Bid (Size)	26.84 (400)
Ask (Size)	26.91 (200)
Prev. Close	26.97
Today's Range	26.00 - 27.12
52wk Range	9.600 - 30.58
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline ↗

Today 13:50 EST

One of these is not like the other.

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Performance

YTD	+13.4%	+13.4%
1 Month	+4.5%	+4.5%
3 Month	-7.3%	-7.3%
6 Month	+61.4%	+61.4%
1 Year	+70.6%	+70.6%

More News

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

Via The Motley Fool

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

February 03, 2026

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally ↗

February 01, 2026

Via The Motley Fool

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

January 14, 2026

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

Via The Motley Fool

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

December 11, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

Via The Motley Fool

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

Via The Motley Fool

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

Via The Motley Fool

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

Via The Motley Fool

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

Via The Motley Fool

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

Via The Motley Fool

Why Centessa Pharmaceuticals Stock Crushed the Market Today ↗

November 12, 2025

Via The Motley Fool

Neural Gold Rush: Is Brain Data the Most Precious Commodity of the Century?

November 12, 2025

Via MarketMinute

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

November 11, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

November 11, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

November 07, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

These stocks that are showing activity before the opening bell on Wednesday. ↗

November 05, 2025

Via Chartmill

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

November 05, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Domino's Pizza Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 20, 2025

Via Benzinga

CENTESSA PHARMACEUTICALS-ADR (NASDAQ:CNTA) Shows Strong Technical Setup for Potential Breakout ↗

October 17, 2025

Via Chartmill

Frequently Asked Questions

Is Centessa Pharmaceuticals plc - American Depositary Shares publicly traded?

Yes, Centessa Pharmaceuticals plc - American Depositary Shares is publicly traded.

What exchange does Centessa Pharmaceuticals plc - American Depositary Shares trade on?

Centessa Pharmaceuticals plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Centessa Pharmaceuticals plc - American Depositary Shares?

The ticker symbol for Centessa Pharmaceuticals plc - American Depositary Shares is CNTA on the Nasdaq Stock Market

What is the current price of Centessa Pharmaceuticals plc - American Depositary Shares?

The current price of Centessa Pharmaceuticals plc - American Depositary Shares is 26.88

When was Centessa Pharmaceuticals plc - American Depositary Shares last traded?

The last trade of Centessa Pharmaceuticals plc - American Depositary Shares was at 02/26/26 02:12 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.